Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma bought for $4.3 billion in 2019. More: Roche overhauls Spark gene therapy unit, recording .4B in full impairment Source: fierce
read moreIn exercising some of his stock options in 2024, BioNTech CEO Uğur Şahin, M.D., scored a whopping 259.5 million euros in calculated compensation, the company said in its annual report. More: By exercising long-held stock options, BioNTech CEO scored €260M
read moreIndian CRDMO Syngene International is paying $36.5 million to acquire Emergent BioSolutions’ shuttered Bayview biologics facility in Baltimore. Syngene ultimately plans to invest around $50 million in the site, which is equipped with multiple production lines for monoclonal antibodies. More:
read more
FSCD therapy meets all endpoints in interim analysis More: Agomab announces positive phase 2a interim results for AGMB-129 Source: News
read more
Scottish Medicines Consortium approves new option for mCRPC patients More: Pfizer’s Talzenna therapy accepted for use within NHS Scotland Source: News
read moreActivist investor Starboard Value proposed four additions to Kenvue’s board last month in an effort to unlock “trapped potential” at the consumer health giant. More: Starboard CEO gets seat on Kenvue's board as activist investor inks 'cooperation agreement' with consumer
read more© 1994 - 2026 B.M. Pharmaceuticals